Fremanezumab reduced migraine attacks and depression symptoms in migraine patients with major depressive disorder.

Several bills introduced in the General Assembly this session are intended to lower health care costs and make health care ...

The FDA has approved a dihydroergotamine-based nasal powder for the acute treatment of migraine with or without aura in ...

Atzumi combines a proprietary advanced powder and device technology to simplify nasal delivery of dihydroergotamine for acute treatment of migraine.

The Food and Drug Administration (FDA) has approved Atzumi ™ (dihydroergotamine) nasal powder for the acute treatment of migraine with or without aura in adults.

Adding perioperative pembrolizumab to standard care can improve EFS in locally advanced head and neck cancer, data suggest.

For a significant number of women with migraine, headaches and other symptoms are linked to fluctuations in hormone levels, especially estrogen levels, which can go up and down significantly ...

US FDA grants fast track designation to OKYO Pharma’s urcosimod to treat neuropathic corneal pain: London Saturday, May 3, 2025, 17:00 Hrs [IST] OKYO Pharma Limited, an ophthalm ...

And once she became a mom, her migraine attacks made it tough to spend time with her kids. “It would take me out of the game, ...

The FDA granted fast track designation to urcosimod to treat neuropathic corneal pain, according to a press release from Okyo Pharma. Urcosimod, formerly called OK-101, is a “lipid conjugated chemerin ...

Get the latest updates on nickel markets: price trends, production growth, and strategic moves in critical minerals to ...

Urcosimod has received FDA fast track designation for neuropathic corneal pain, enabling expedited regulatory processes and ...